"rationale","id","uuid:ID","versionIdentifier","instanceType"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1","034f1066-6ebd-4f2e-ba93-d6dd6a4feb51","2","StudyVersion"
